MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide.

PPARγ:18.25 μM

糖尿病db/db和MS-NASH小鼠通过口腔灌胃接受MSDC-0602K治疗，通过皮下(s.c.)注射接受Liraglutide治疗，或接受MSDC-0602K与Liraglutide的联合治疗。这种联合治疗可能是对付糖尿病和非酒精性脂肪肝炎的有效疗法。动物模型：五周龄的雄性db/db小鼠背景为C57BL/6J，以及年龄/性别匹配的db/+对照小鼠[1]。剂量：MSDC-0602K 30 mg/kg；Liraglutide 0.2 mg/kg。给药方式：MSDC-0602K每天一次通过灌胃给药，Liraglutide每隔一天通过皮下注射给药，或MSDC-0602K+Liraglutide联合给药。结果：单独给予MSDC-0602K或与Liraglutide联合给药时，可以纠正血糖并减少胰岛素血症。然而，MSDC-0602K + Liraglutide联合使用在改善葡萄糖耐受和肝组织学方面效果更显著[1]。